8-K Announcements
6Material company update
Apr 16, 2026·SEC
Material company update
Mar 23, 2026·SEC
Material company update
Mar 12, 2026·SEC
Xilio Therapeutics, Inc.(XLO)Earnings, Financials & Key Ratios
XLO•NASDAQ
$7.90
$660M mkt cap·Price updated May 6, 2026
AboutXilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.Show more
- Revenue$44M+589.9%
- EBITDA-$42M+28.8%
- Net Income$0+100.0%
- EPS (Diluted)-4.19+72.5%
- EBITDA Margin-95.92%+89.7%
- Operating Margin-95.92%+90.0%
- Debt/Equity0.20-57.4%
XLO Key Insights
Xilio Therapeutics, Inc. (XLO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
No significant strengths identified
✗Weaknesses
- ✗Weak Piotroski F-Score: 3/9
- ✗Negative free cash flow
- ✗Shares diluted 100.0% in last year
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 18.7x book value
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
XLO Price & Volume
Xilio Therapeutics, Inc. (XLO) stock price & volume — 10-year historical chart
Loading chart...
XLO Growth Metrics
Xilio Therapeutics, Inc. (XLO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM589.88%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM100%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM77.99%
Return on Capital
10 Years-85.68%
5 Years-82.89%
3 Years-97.53%
Last Year-59.04%
XLO Recent Earnings
Xilio Therapeutics, Inc. (XLO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 2/12 qtrs (29%)
Q2 2026Latest
Mar 23, 2026EPS
$0.85
Est $1.68
+49.4%
Revenue
$14M
Est $11M
+25.6%
Q4 2025
Nov 13, 2025EPS
$0.03
Est $0.45
+93.3%
Revenue
$19M
Est $19M
+2.3%
Q3 2025
Aug 14, 2025EPS
$0.16
Est $1.10
+85.5%
Revenue
$8M
Est $19M
-56.6%
Q2 2025
May 8, 2025EPS
$0.18
Est $2.70
+93.3%
Revenue
$3M
Est $23M
-87.4%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 23, 2026 | $0.85vs $1.68+49.4% | $14Mvs $11M+25.6% |
| Q4 2025 | Nov 13, 2025 | $0.03vs $0.45+93.3% | $19Mvs $19M+2.3% |
| Q3 2025 | Aug 14, 2025 | $0.16vs $1.10+85.5% | $8Mvs $19M-56.6% |
| Q2 2025 | May 8, 2025 | $0.18vs $2.70+93.3% | $3Mvs $23M-87.4% |
Based on last 12 quarters of dataView full earnings history →
XLO Peer Comparison
Xilio Therapeutics, Inc. (XLO) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 NKTX | 234.54M | 3.32 | -2.08 | -30.37% | 0.20 | |||
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% | |||
 CLDX | 2.29B | 34.39 | -8.82 | -78.63% | -172.53% | -49.09% | 0.00 | |
 TGTX | 6.7B | 41.97 | 15.15 | 87.32% | 65.95% | 87.36% | 0.40 | |
 NUVL | 6.92B | 104.26 | -26.53 | -45.12% | ||||
 ALKS | 5.89B | 35.32 | 24.70 | -5.25% | 9.78% | 8.82% | 0.04 |
Compare XLO vs Peers
Xilio Therapeutics, Inc. (XLO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
XLO Income Statement
Xilio Therapeutics, Inc. (XLO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 6.34M | 43.77M |
| Revenue Growth % | - | - | - | - | - | - | 589.88% |
| Cost of Goods Sold | 240K | 1.06M | 1.5M | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - |
| Gross Profit | -240K▲ 0% | -1.06M▼ 343.8% | -1.5M▼ 40.8% | 0▲ 100.0% | 0▲ 0% | 6.34M▲ 0% | 0▼ 100.0% |
| Gross Margin % | - | - | - | - | - | 100% | - |
| Gross Profit Growth % | - | -343.75% | -40.75% | 100% | - | - | -100% |
| Operating Expenses | 18.79M | 53.5M | 73.55M | 89.15M | 79.13M | 66.93M | 85.75M |
| OpEx % of Revenue | - | - | - | - | - | 1054.95% | 195.92% |
| Selling, General & Admin | 4.53M | 9.59M | 22.36M | 29.95M | 27M | 24.78M | 29.71M |
| SG&A % of Revenue | - | - | - | - | - | 390.57% | 67.88% |
| Research & Development | 14.26M | 43.91M | 51.19M | 59.2M | 52.14M | 41.21M | 56.04M |
| R&D % of Revenue | - | - | - | - | - | 649.61% | 128.04% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 937K | 0 |
| Operating Income | -19.03M▲ 0% | -54.56M▼ 186.8% | -75.04M▼ 37.5% | -89.15M▼ 18.8% | -79.13M▲ 11.2% | -60.58M▲ 23.4% | -41.98M▲ 30.7% |
| Operating Margin % | - | - | - | - | - | -954.95% | -95.92% |
| Operating Income Growth % | - | -186.77% | -37.54% | -18.8% | 11.24% | 23.44% | 30.7% |
| EBITDA | -18.79M | -53.5M | -73.55M | -87.3M | -77.23M | -58.94M | -41.98M |
| EBITDA Margin % | - | - | - | - | - | -929.04% | -95.92% |
| EBITDA Growth % | - | -184.76% | -37.47% | -18.71% | 11.53% | 23.69% | 28.77% |
| D&A (Non-Cash Add-back) | 240K | 1.06M | 1.5M | 1.85M | 1.9M | 1.64M | 0 |
| EBIT | -17.31M | -54.62M | -75.2M | -89.15M | -79.13M | -59.65M | 0 |
| Net Interest Income | 0 | -599.4K | -599.4K | 0 | 0 | -100K | 0 |
| Interest Income | 0 | 600 | 600 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 600K | 600K | 0 | 0 | 100K | 0 |
| Other Income/Expense | 1.72M | -656K | -756K | 927K | 2.73M | 2.34M | 0 |
| Pretax Income | -17.31M▲ 0% | -55.22M▼ 219.0% | -75.8M▼ 37.3% | -88.22M▼ 16.4% | -76.4M▲ 13.4% | -58.24M▲ 23.8% | 0▲ 100.0% |
| Pretax Margin % | - | - | - | - | - | -918.05% | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | - |
| Net Income | -17.31M▲ 0% | -55.22M▼ 219.0% | -75.8M▼ 37.3% | -88.22M▼ 16.4% | -76.4M▲ 13.4% | -58.24M▲ 23.8% | 0▲ 100.0% |
| Net Margin % | - | - | - | - | - | -918.05% | - |
| Net Income Growth % | - | -218.98% | -37.27% | -16.39% | 13.4% | 23.77% | 100% |
| Net Income (Continuing) | -17.31M | -55.22M | -75.8M | -88.22M | -76.4M | -58.24M | 0 |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -592.06▲ 0% | -1475.88▼ 149.3% | -189.28▲ 87.2% | -45.08▲ 76.2% | -38.92▲ 13.7% | -15.26▲ 60.8% | -4.19▲ 72.5% |
| EPS Growth % | - | -149.28% | 87.18% | 76.18% | 13.66% | 60.79% | 72.54% |
| EPS (Basic) | -592.06 | -1475.88 | -189.28 | -45.08 | -38.92 | -15.26 | -4.19 |
| Diluted Shares Outstanding | 29.24K | 37.41K | 400.45K | 1.96M | 1.96M | 3.82M | 83.59M |
| Basic Shares Outstanding | 29.24K | 37.41K | 400.45K | 1.96M | 1.96M | 3.82M | 83.59M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
XLO Balance Sheet
Xilio Therapeutics, Inc. (XLO) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 51.1M | 20.59M | 202.52M | 124.5M | 48.13M | 60.23M | 145.03M |
| Cash & Short-Term Investments | 48.84M | 19.24M | 198.05M | 120.39M | 44.7M | 55.29M | 137.53M |
| Cash Only | 48.84M | 19.24M | 198.05M | 120.39M | 44.7M | 55.29M | 137.53M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 1.01M | 0 | 4.46M | 4.11M | 3.42M | 4.94M | 7.5M |
| Total Non-Current Assets | 11.62M | 15.73M | 19.08M | 14.67M | 12.8M | 10.84M | 9.66M |
| Property, Plant & Equipment | 9.87M | 14.06M | 13.9M | 12.84M | 11.2M | 9.06M | 7.85M |
| Fixed Asset Turnover | - | - | - | - | - | 0.70x | 5.57x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 194K | 0 | 1.55M | 1.56M | 0 | 1.78M | 0 |
| Other Non-Current Assets | 1.55M | 1.66M | 90K | 267K | 1.6M | 0 | 1.81M |
| Total Assets | 62.72M▲ 0% | 36.32M▼ 42.1% | 221.6M▲ 510.2% | 139.16M▼ 37.2% | 60.93M▼ 56.2% | 71.08M▲ 16.7% | 154.69M▲ 117.6% |
| Asset Turnover | - | - | - | - | - | 0.09x | 0.28x |
| Asset Growth % | - | -42.1% | 510.18% | -37.2% | -56.22% | 16.66% | 117.64% |
| Total Current Liabilities | 5.21M | 22.16M | 12.78M | 21.12M | 15.96M | 27.26M | 56.27M |
| Accounts Payable | 2.52M | 5.44M | 3.14M | 3.13M | 1.05M | 2.57M | 3.17M |
| Days Payables Outstanding | 3.83K | 1.87K | 765.55 | - | - | - | - |
| Short-Term Debt | 0 | 2.33M | 883K | 6.67M | 3.31M | 0 | 1.34M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 13.52M | 40.02M |
| Other Current Liabilities | 1.92M | 0 | 3.61M | 82K | 6.9M | 4.21M | 14.91M |
| Current Ratio | 9.81x | 0.93x | 15.85x | 5.89x | 3.02x | 2.21x | 2.58x |
| Quick Ratio | 9.81x | 0.93x | 15.85x | 5.89x | 3.02x | 2.21x | 2.58x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 19M | 19.45M | 23.39M | 12.4M | 8.14M | 26.22M | 63.14M |
| Long-Term Debt | 9.61M | 7.81M | 9.63M | 3.17M | 0 | 0 | 5.61M |
| Capital Lease Obligations | 9.02M | 11.1M | 10.22M | 9.19M | 8.14M | 6.95M | 0 |
| Deferred Tax Liabilities | 0 | 0 | 3.54M | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 374K | 540K | 0 | 45K | 0 | 0 | 57.53M |
| Total Liabilities | 24.21M | 41.6M | 36.17M | 33.52M | 24.1M | 53.48M | 119.41M |
| Total Debt | 18.63M | 21.89M | 20.74M | 19.94M | 11.46M | 8.14M | 6.95M |
| Net Debt | -30.21M | 2.65M | -177.32M | -100.45M | -33.25M | -47.15M | -130.58M |
| Debt / Equity | 0.48x | - | 0.11x | 0.19x | 0.31x | 0.46x | 0.20x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | - | -90.94x | -125.07x | - | - | -605.82x | - |
| Total Equity | 38.51M▲ 0% | -5.29M▼ 113.7% | 185.43M▲ 3608.6% | 105.65M▼ 43.0% | 36.83M▼ 65.1% | 17.6M▼ 52.2% | 35.27M▲ 100.4% |
| Equity Growth % | - | -113.72% | 3608.59% | -43.03% | -65.14% | -52.21% | 100.44% |
| Book Value per Share | 1317.21 | -141.26 | 463.05 | 54.00 | 18.75 | 4.60 | 0.42 |
| Total Shareholders' Equity | 38.51M | -5.29M | 185.43M | 105.65M | 36.83M | 17.6M | 35.27M |
| Common Stock | 0 | 0 | 3K | 3K | 3K | 5K | 36.89M |
| Retained Earnings | -29.87M | -85.09M | -160.89M | -249.11M | -325.51M | -383.75M | -418.79M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
XLO Cash Flow Statement
Xilio Therapeutics, Inc. (XLO) cash flow — operating, investing & free cash flow history
| Line item | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -17.84M | -36.09M | -80.75M | -75.72M | -68.62M | -18.38M | -4.99M |
| Operating CF Margin % | - | - | - | - | - | -289.69% | -11.41% |
| Operating CF Growth % | - | -102.27% | -123.74% | 6.23% | 9.38% | 73.22% | 72.84% |
| Net Income | -17.31M | -55.22M | -75.8M | -88.22M | -76.4M | -58.24M | -35.04M |
| Depreciation & Amortization | 240K | 1.06M | 1.5M | 1.85M | 1.9M | 1.64M | 1.54M |
| Stock-Based Compensation | 112K | 1.3M | 4.96M | 8.42M | 7.38M | 6.43M | 6.94M |
| Deferred Taxes | -1.74M | 0 | 222K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 56K | 165K | 173K | 224K | 160K | 3K | 21.56M |
| Working Capital Changes | 797K | 16.6M | -11.8M | 2M | -1.66M | 31.78M | 0 |
| Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 970K | 2.93M | -2.82M | 485K | -2.06M | 1.53M | 152K |
| Cash from Investing | -715K | -2.19M | -1.1M | -1.87M | -486K | -36K | -518K |
| Capital Expenditures | -715K | -2.19M | -1.1M | -1.87M | -486K | -36K | -518K |
| CapEx % of Revenue | - | - | - | - | - | 0.57% | 1.18% |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash from Financing | 60.02M | 10.03M | 260.67M | -69K | -6.55M | 29.2M | 87.78M |
| Debt Issued (Net) | 9.95M | -99K | -110K | -85K | -6.75M | -3.38M | 0 |
| Equity Issued (Net) | 60.02M | 9.97M | 261.25M | 16K | 202K | 6.83M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 2.81M |
| Other Financing | -9.95M | 159K | -467K | 0 | 0 | 25.75M | 87.78M |
| Net Change in Cash | 41.46M▲ 0% | -28.25M▼ 168.1% | 178.82M▲ 733.0% | -77.67M▼ 143.4% | -75.68M▲ 2.6% | 10.78M▲ 114.2% | 82.27M▲ 663.0% |
| Free Cash Flow | -18.56M▲ 0% | -38.28M▼ 106.3% | -81.85M▼ 113.8% | -77.59M▲ 5.2% | -69.11M▲ 10.9% | -18.41M▲ 73.4% | -5.51M▲ 70.1% |
| FCF Margin % | - | - | - | - | - | -290.26% | -12.59% |
| FCF Growth % | - | -106.27% | -113.83% | 5.21% | 10.93% | 73.35% | 70.08% |
| FCF per Share | -634.77 | -1023.14 | -204.40 | -39.66 | -35.19 | -4.82 | -0.07 |
| FCF Conversion (FCF/Net Income) | 1.03x | 0.65x | 1.07x | 0.86x | 0.90x | 0.32x | - |
| Interest Paid | 14K | 536K | 492K | 0 | 0 | 62K | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
XLO Key Ratios
Xilio Therapeutics, Inc. (XLO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -44.95% | -332.39% | -84.15% | -60.62% | -107.25% | -214.02% | - |
| Return on Invested Capital (ROIC) | - | -1446.27% | -2056% | -1004.46% | -1351.78% | - | - |
| Gross Margin | - | - | - | - | - | 100% | - |
| Net Margin | - | - | - | - | - | -918.05% | - |
| Debt / Equity | 0.48x | - | 0.11x | 0.19x | 0.31x | 0.46x | 0.20x |
| Interest Coverage | - | -90.94x | -125.07x | - | - | -605.82x | - |
| FCF Conversion | 1.03x | 0.65x | 1.07x | 0.86x | 0.90x | 0.32x | - |
| Revenue Growth | - | - | - | - | - | - | 589.88% |
XLO SEC Filings & Documents
Xilio Therapeutics, Inc. (XLO) SEC filings — annual & quarterly reports (10-K, 10-Q)
XLO Frequently Asked Questions
Xilio Therapeutics, Inc. (XLO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Xilio Therapeutics, Inc. (XLO) reported $43.8M in revenue for fiscal year 2025.
Xilio Therapeutics, Inc. (XLO) grew revenue by 589.9% over the past year. This is strong growth.
Xilio Therapeutics, Inc. (XLO) reported a net loss of $0.0M for fiscal year 2025.
Dividend & Returns
Xilio Therapeutics, Inc. (XLO) had negative free cash flow of $5.5M in fiscal year 2025, likely due to heavy capital investments.
Explore More XLO
Xilio Therapeutics, Inc. (XLO) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates